XOMA Corporation (XOMAP) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2025
Loading P/E history...
XOMAP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, XOMA Corporation (XOMAP) trades at a price-to-earnings ratio of 17.3x, with a stock price of $25.33 and trailing twelve-month earnings per share of $1.75.
The current P/E is 34% below its 5-year average of 26.4x. Over the past five years, XOMAP's P/E has ranged from a low of 12.6x to a high of 89.1x, placing the current valuation at the 36th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, XOMAP trades at a 22% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
The PEG ratio of 1.30 (P/E divided by 188% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, XOMAP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMAP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XOMAP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $358B | 85.5 | - | -1% | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4Lowest | 0.73Best | +8%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
XOMAP Historical P/E Data (2020–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $26.87 | $1.54 | 17.4x | -34% |
| FY2025 Q3 | $26.47 | $2.10 | 12.6x | -52% | |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $25.84 | $0.29 | 89.1x | +237% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $24.32 | $1.66 | 14.7x | -45% |
| FY2022 Q2 | $25.40 | $1.62 | 15.7x | -41% | |
| FY2022 Q1 | $26.34 | $1.82 | 14.5x | -45% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $26.30 | $1.39 | 18.9x | -28% |
| FY2021 Q3 | $26.48 | $0.76 | 34.8x | +32% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $26.55 | $1.05 | 25.2x | -5% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $25.00 | $0.94 | 26.5x | +0% |
| FY2020 Q4 | $24.99 | $1.17 | 21.3x | -19% |
Average P/E for displayed period: 26.4x
See XOMAP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XOMAP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XOMAP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXOMAP — Frequently Asked Questions
Quick answers to the most common questions about buying XOMAP stock.
Is XOMAP stock overvalued or undervalued?
XOMAP trades at 17.3x P/E, below its 5-year average of 26.4x. At the 36th percentile of historical range, the stock is priced at a discount to its own history.
How does XOMAP's valuation compare to peers?
XOMA Corporation P/E of 17.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is XOMAP's PEG ratio?
XOMAP PEG ratio is 1.30. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 2020-2025.